No Data
No Data
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" Segment Highlighting Key Learnings From First-In-Human Trial and Extension Into Visceral Cancer Pain
Maxim Group Initiates Autonomix Medical(AMIX.US) With Buy Rating, Announces Target Price $5
Autonomix Medical Reports Positive Results In First Human Trial For Cancer Pain, Stock Down
Express News | Autonomix Medical Inc - No Device or Procedure-Related Serious Adverse Events
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain
Autonomix Medical Initiated at Buy by Maxim Group